Hi {{ session.user.profile.firstName }}

Retention Mechanisms in HILIC Chromatography: Robust Method Development

Manage webcast
David S. Bell, Ph.D.
Hydrophilic interaction liquid chromatography (HILIC), especially in conjunction with mass spectrometry (MS), has become a powerful tool for the analysis of a wide variety of challenging analytes. Applications of the technique have increased dramatically over the past decade, especially for the analysis of polar analytes where reversed-phase chromatography suffers. HILIC conditions employ a high percentage of acetonitrile which enables facilitated solvent evaporation in LC/MS sources and thus often an increase in analyte response when compared to more aqueous based systems. The increased retention of polar analytes afforded by HILIC provides improved selectivity and decreases the impact of endogenous species, often leading to improved qualitative and quantitative analyses.

Although HILIC has proven useful, it has also been thwarted with complications including difficulties in method development and method robustness.

In this presentation, studies investigating the underlying retention mechanisms dominant in HILIC chromatography are presented and discussed. Along with reversed-partitioning HILIC is well known to exhibit, ion-exchange and the interplay of the dominant mechanisms are unveiled and used to develop a model of overall retention and selectivity. Interactions that operate using different stationary phase chemistries and conditions are presented. The impact of analyte polarity and charge as well as the variations caused by high percentages of organic on these physiochemical parameters are highlighted. Throughout the discussion, examples of use and misuse of HILIC are employed to illustrate these important concepts to build a solid fundamental foundation for efficient and effective use of this powerful technique.
Jun 28 2012
55 mins
Retention Mechanisms in HILIC Chromatography:  Robust Method Development
More from this community:

Medical Research

  • Date
  • Rating
  • Views
  • Achieving your ADME/Tox testing goals requires experience, quality data, and proper alignment with regulatory guidance. Failure to meet these important requirements can put your drug discovery and pre-clinical goals at risk.
    This presentation will provide an informative overview of how you can advance and reach your pre-clinical drug discovery goals. It will discuss the importance of core contract research capabilities, including enzyme induction, enzyme inhibition, and transporter interaction. In addition, we will review new capabilities and opportunities including CYP induction and SLC transporter assay services – all designed to align with regulatory agency guidance documents.

    Speaker Bio:
    David Stresser is the Program Manager of Corning® Gentest℠ Contract Research Services at Corning Life Sciences since 2001, having held prior positions of Product Manager and Study Director since joining Corning in 1998. Prior to this, he was a post-doctoral associate in the laboratory of David Kupfer at the University of Massachusetts Medical School in Worcester, Massachusetts. He did his graduate work in the laboratory of David E. Williams at Oregon State University in Corvallis, Oregon receiving a Ph.D. in toxicology in 1994. Dr. Stresser has authored or co-authored 40 articles or book chapters in the field of drug metabolism and has been an invited speaker at various national and international meetings, pharmaceutical companies, and universities.
  • Presentation 1: Jason Causon, Senior Applications Specialist, Sciex

    Development of bioanalytical LC-MS methods for the detection of therapeutic peptides and the proteolytic fragments of larger proteins and antibodies is growing along with the increasing number of peptide and protein drugs entering clinical research and development. Development of these methods present challenges that are different to small molecule method development because of the multiple charge states possible for a given peptide, the abundance of product ion possibilities and the large number of proteolytic fragments possible from a protein digest. In addition to optimizing for sensitivity, on-column HPLC method development is time consuming for the same reasons. In this webinar we present an automated tuning and optimization workflow with on-column validation using DiscoveryQuantTM 3.0 software with the new ChromaTune feature to overcome some of these challenges and make the optimization of peptide MRM methods easier and less time consuming.

    Presentation 2: Remco van Soest, Product Manager, Sciex

    Electrospray Ionization efficiency increases at lower flow rates. In this Webinar we will discuss how microLC can help you improve sensitivity in sample limited applications in bio-analysis by LC-MS. In order to analyse the same volume of sample as is typically injected in a conventional LC-MS system, up to 50 µL, we have developed a microLC system that allows for fast on-line pre-concentration on a short trap column. Because of the higher flow rates that can be used for loading the sample on the trap-column, sample throughput is not affected by using microLC flow rates for the LC-MS analysis.
  • Cell therapy is the fastest growing segment of regenerative medicine. Cell therapy is comprised of immune cell therapy and stem cell therapy, with stem cell therapy making up the largest part of this market: it is estimated that the global stem cell therapy market will reach $40 billion by 2020 and $180 billion by 2030.

    Many factors determine the rate at which the stem cell therapy market advances. It is driven by the success of stem cell treatments in curing life-threatening diseases such as cancer, heart diseases and neuromuscular diseases in the worlds aging populations. In contrast, stem cell market growth rate is hindered by manufacturing and regulatory concerns. For example, if only 20% of the 318 global late stage clinical trials are approved for release on the market, there will not be enough stem cell therapy manufacturing facilities to produce the 64 resulting products. This is due, in part, to funding concerns, the high cost of build-out as well as cGMP compliance, standardization of production processes, and ever changing industry regulations.

    Join us as we discuss these and other key topics.
  • RNAi screening has made it possible to identify new genes, or gene networks, that are involved in a wide vari¬ety of biological processes, including assays relevant to signal transduction, cell viability, cell morphology, protein localization and function, drug resistance, and responses of host cells to pathogens. As such, RNAi continues to help us gain critical insights into the mechanisms underlying human disease and accelerate the development of treatments for cancer and a host of other disorders. The intersection between RNAi screening and complementary approaches such as CRISPR-Cas9-mediated genome editing has opened up new opportunities for assay development, screening and validation. The successful implementation of genome-editing technologies in several species suggests this will serve as an important and relevant tool for validation studies in numerous cell lines and model systems. Additionally, RNAi rescue experiments using LentiORFs serve an important role in further validating and boosting confidence of screened hits. As we continue to develop new strategies to improve genome-wide RNAi screening and validation, the significance of RNAi as a research tool will remain for many years to come.
  • Computer Aided Synthetic Design: How ARChem Can Improve Your Efficiency and Creativity

    Are you looking for a better way to synthesize a target molecule?

    Have you hit a roadblock in the lab or need an extra burst of creative thinking?

    Join Orr Ravitz at 10:00 AM (EDT) on July 16th for an overview of the future of synthetic design and the software that can help improve your efficiency and creativity in the lab with ARChem.

    He will discuss how medicinal chemists, process chemists and material scientists use ARChem as an idea generator – a tool for route scouting, for brain storming sessions, for the daily synthesis planning and potentially provide an alternative that gets you to curated experimental pathways faster than exploring the literature.

    This webinar will cover:

    ◦The technology behind ARChem and real life case studies
    ◦How ARChem can improve your productivity and creativity in the lab
    ◦Future developments of our synthetic design software
  • RNAi screening has made it possible to identify new genes, or gene networks, that are involved in a wide vari¬ety of biological processes, including assays relevant to signal transduction, cell viability, cell morphology, protein localization and function, drug resistance, and responses of host cells to pathogens. As such, RNAi continues to help us gain critical insights into the mechanisms underlying human disease and accelerate the development of treatments for cancer and a host of other disorders. The intersection between RNAi screening and complementary approaches such as CRISPR-Cas9-mediated genome editing has opened up new opportunities for assay development, screening and validation. The successful implementation of genome-editing technologies in several species suggests this will serve as an important and relevant tool for validation studies in numerous cell lines and model systems. Additionally, RNAi rescue experiments using LentiORFs serve an important role in further validating and boosting confidence of screened hits. As we continue to develop new strategies to improve genome-wide RNAi screening and validation, the significance of RNAi as a research tool will remain for many years to come.
  • Understanding your customers is fundamental to effective communication. Current segmentation strategies draw on ever more detailed information about how patients, physicians and payers behave through the use of open source, social media and real world data. However, segmentation still lacks clear insight into why these stakeholders behave as they do – and therefore how best to change their behaviour.
    Working with behavioural change experts Hamell, this one hour live discussion will look at why current segmentation strategies are failing, and the importance of understanding what drives patient or customer behaviour. Using case studies, speakers will explore how segmenting by behavioural drivers can create advanced, effective strategies to change patient, customer and payer behaviour.
    This event will focus on three key areas:

    •The theory behind behavioural segmentation and how it challenges the status quo
    •Benefits of behavioural segmentation communication strategies and the problems answered by behavioural segmentation strategies
    •Behavioural segmentation in action: practical application of this approach
  • How to Prepare and What to Ask of Your Suppliers:

    In an effort to thwart fraudulent medical manufacturing practices, the European Commission published a Commission Recommendation (2013/473/EU) focusing on the assessment and auditing practices of notified bodies in the field of medical devices.
    A particular emphasis in this Recommendation has been placed on unannounced audits. Unannounced audits are additional assessments by notified bodies of manufacturers and/or their critical material suppliers. Auditors commissioned by the notified body will be able to arrive on site without giving the manufacturer prior notice and proceed with inspection. Over 5,000 unannounced audits are expected this year alone and come in addition to the initial surveillance or renewal audits of a three-year certification cycle.

    Now is the time to make sure you and your supplier’s quality and supply chain management systems are in place and you have full transparency. Join us for this informational webinar discussing this trending regulatory standard and learn about what you and your suppliers should be doing to proactively prepare.

Embed in website or blog

Successfully added emails: 0
Remove all
  • Title: Retention Mechanisms in HILIC Chromatography: Robust Method Development
  • Live at: Jun 28 2012 6:00 pm
  • Presented by: David S. Bell, Ph.D.
  • From:
Your email has been sent.
or close
You must be logged in to email this